| Issue |
Med Sci (Paris)
Volume 33, Number 11, Novembre 2017
|
|
|---|---|---|
| Page(s) | 1003 - 1006 | |
| Section | Forum | |
| DOI | https://doi.org/10.1051/medsci/20173311020 | |
| Published online | 04 December 2017 | |
Immunothérapie « CAR-T » : une autorisation qui fait date
Chroniques génomiques
CAR-T immunotherapy, a regulatory milestone
UMR 7268 ADÉS, Aix-Marseille, Université/EFS/CNRS, Espace éthique méditerranéen, hôpital d’adultes la Timone, 264, rue Saint-Pierre, 13385 Marseille Cedex 05, France ;
CoReBio PACA, case 901, parc scientifique de Luminy, 13288 Marseille Cedex 09, France
*
bertrand.jordan@univ-amu.fr ; brjordan@orange.fr
Abstract
The first therapy based on chimeric antigen receptors has been approved by the FDA. It gives excellent results in recurrent paediatric ALL; its cost is very high but fairly consistent with the clinical benefit (long term remission approaching a cure). In spite of their complexity and cost, CAR-T therapies will probably end up playing a very significant role in cancer therapy.
© 2017 médecine/sciences – Inserm
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.